P052注射液不仅可以通过激动GLP-1受体促进胰岛素分泌、降低血糖和减轻体重，还能通过激动GCGR 增加能量消耗、增强减重疗效，同时改善肝脏脂肪代谢。临床前数据显示，GLP-1R/GCGR双靶点创新 药P052注射液的降糖效果与GLP-1单靶点药物司美格鲁肽注射液相似，减重效果显着优于司美格鲁肽注 射液。 人民财讯9月9日电，四环医药(00460.HK)9月9日早间在港交所公告，集团旗下非全资附属公司惠升生物 制药股份有限公司自主研发的胰高血糖素样肽-1受体（GLP-1R）╱胰高血糖素受体（GCGR）双靶点激 动剂创新药P052注射液新药临床试验申请获得国家药监局药品审评中心默示许可，用于治疗2型糖尿 病、超重或肥胖症。 ...

糖尿病领域为惠升生物重点布局领域，本次GLP-1R/GCGR双靶点激动剂创新药P052注射液获批IND， 不仅是惠升生物创新研发实力的有力证明，也意味着惠升生物在糖尿病药物研发方面迈出了重要的一 步，为集团糖尿病业务长期发展注入动能，进一步提升在糖尿病行业的核心竞争力与市场价值。 四环医药(00460)发布公告，集团旗下非全资附属公司惠升生物制药股份有限公司(惠升生物)自主研发的 胰高血糖素样肽-1受体(GLP-1R)╱胰高血糖素受体(GCGR)双靶点激动剂创新药P052注射液新药临床试 验申请(IND)获得国家药品监督管理局(NMPA)药品审评中心(CDE)默示许可，用于治疗2型糖尿病、超 重或肥胖症。 P052注射液不仅可以通过激动GLP-1受体促进胰岛素分泌、降低血糖和减轻体重，还能通过激动GCGR 增加能量消耗、增强减重疗效，同时改善肝脏脂肪代谢。临床前数据显示，GLP-1R/GCGR双靶点创新 药P052注射液的降糖效果与GLP-1单靶点药物司美格鲁肽注射液相似，减重效果显著优于司美格鲁肽注 射液。 ...

Core Viewpoint - The announcement highlights the approval of the clinical trial application for the innovative drug P052 injection, developed by Huisheng Biopharmaceutical Co., Ltd., a non-wholly owned subsidiary of Sihuan Pharmaceutical, for the treatment of type 2 diabetes and obesity [1] Group 1: Drug Development - The P052 injection is a dual-target agonist for GLP-1R and GCGR, which promotes insulin secretion, lowers blood sugar, and aids in weight loss [1] - Preclinical data indicates that the blood sugar-lowering effect of P052 is similar to that of the single-target drug semaglutide, while its weight loss effect is significantly better [1] Group 2: Strategic Importance - The approval of the IND for the P052 injection is a strong testament to Huisheng Biopharmaceutical's innovative research capabilities [1] - This development marks a significant step in the company's focus on diabetes drug research, enhancing its core competitiveness and market value in the diabetes sector [1]

根据披露，P052注射液不仅可以通过激动GLP-1受体促进胰岛素分泌、降低血糖和减轻体重，还能通过 激动GCGR增加能量消耗、增强减重疗效，同时改善肝脏脂肪代谢。临床前数据显示，GLP-1R/GCGR 双靶点创新药P052注射液的降糖效果与GLP-1单靶点药物司美格鲁肽注射液相似，减重效果显著于司美 格鲁肽注射液。 格隆汇9月9日丨四环医药(00460.HK)宣布，集团旗下非全资附属公司惠升生物制药股份有限公司("惠升 生物")自主研发的胰高血糖素样肽-1受体("GLP-1R")╱胰高血糖素受体("GCGR")双靶点激动剂创新药 P052注射液新药临床试验申请("IND")获得国家药品监督管理局("NMPA")药品审评中心("CDE")默示许 可，用于治疗2型糖尿病、超重或肥胖症。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 就 因 本 公 告 全部或任何部份內容而產生或因倚賴該等內容而引致之任何損失承擔任何責 任。 Sihuan Pharmaceutical Holdings Group Ltd. 四環醫藥控股集團有限公司 （於百慕達註冊成立的有限公司） （股份代號：0460） GLP-1R/GCGR雙靶點藥物作為GLP-1藥 物 領 域 的 創 新 方 向，具 有 廣 闊 的 市 場 潛 力。根據國際糖尿病聯盟(IDF)數據顯示，二零二四年中國成年糖尿病患者達1.48 億 人，預 計 二 零 五 零 年 將 增 長 至1.683億 人；根 據 國 家 衛 健 委 數 據 顯 示，我 國 成 人超重肥胖率已突破50%，若 不 得 到 有 效 遏 制，到 二 零 三 零 年 這 一 比 例 將 達 到 70.5%。根 據 諾 和 諾 德 財 報，二 零 二 五 年 上 半 年，諾 和 諾 德 的 司 美 格 魯 肽 注 射 液 全球銷售額1,014億 丹 麥 克 ...

多个重要指数的成份股，即将迎来调整！ 9月8日，恒生指数成份股调整将正式生效。恒生生物科技指数、恒生综合指数的成份股也有重大调整，所有变动将于9月8日起生效。 另外，根据上交所和中证指数公司此前发布的公告，科创50指数、科创100指数样本也将进行调整，并于9月12日收市后生效。 来看详细报道！ 周一生效！泡泡玛特等将加入港股重要指数 近日，恒生指数有限公司宣布了截至2025年二季度的恒生指数系列检讨结果，所有变动将于9月8日(星期一)起生效。 其中，恒生指数成份股数量将由85只增加至88只，加入了中国电信、京东物流、泡泡玛特。恒生指数成份股的变动亦适用于恒指港股通指数。 恒生中国企业指数成份股数量维持50只。该指数的成份股将加入泡泡玛特，剔除极兔速递-W。恒生中国企业指数成份股公司的变动亦适用于恒生 中国企业精明指数。 其中，生益电子将被调入科创50指数，埃夫特、中科蓝讯等5只证券将被调入科创100指数。 恒生生物科技指数成份股变动较大，数量由50只减少至30只。该指数的成份股将加入映恩生物-B；剔除四环医药、先健科技、丽珠医药、康臣药 业、爱康医疗、锦欣生殖、石四药集团、乐普生物-B、康诺亚-B、微创脑科学 ...

重要消息有这些 恒生指数有限公司此前宣布2025年第二季度之恒生指数系列检讨结果，成份股变动将于9月8日起生效。 易会满涉嫌严重违纪违法，目前正接受中央纪委国家监委纪律审查和监察调查。 日本首相石破茂宣布辞职。 宏观·要闻 易会满被查 据人民日报消息，十四届全国政协经济委员会副主任易会满涉嫌严重违纪违法，目前正接受中央纪委国 家监委纪律审查和监察调查。 美国8月非农就业人数增加2.2万 当地时间7日18时左右，日本首相、自民党总裁石破茂在首相官邸举行紧急记者会，宣布决定辞去自民 党总裁职务。 金融·证券 恒指季度检讨结果出炉 恒生指数有限公司此前宣布2025年第二季度之恒生指数系列检讨结果，成份股变动将于9月8日（星期 一）起生效。 恒生指数成份股数目将由85只增加至88只。成份股将加入中国电信、京东物流、泡泡玛特。 恒生指数成份股的变动亦适用于恒指港股通指数。恒生中国企业指数成份股数目维持50只。成份股将加 入泡泡玛特；剔除极兔速递—W。 恒生中国企业指数成分股公司的变动亦适用于恒生中国企业精明指数。恒生科技指数成份股没有变动， 成份股数目维持30只。恒生生物科技指数成份股数目由50只减少至30只。成份股将 ...

Group 1: Market Updates - The Hang Seng Index Company announced the results of the Hang Seng Index series review for the second quarter of 2025, with constituent stock changes effective from September 8 [1][8] - The number of constituent stocks in the Hang Seng Index will increase from 85 to 88, with additions including China Telecom, JD Logistics, and Pop Mart [9] - The Hang Seng Composite Index will see its constituent stocks increase from 502 to 504, adding China Foods and Hengrui Medicine among others [11] Group 2: Economic Indicators - As of the end of August 2025, China's foreign exchange reserves stood at $33,222 billion, an increase of $29.9 billion from the end of July, reflecting a rise of 0.91% [12][13] - The People's Bank of China has increased its gold reserves for the tenth consecutive month, with reserves reaching 7,402 million ounces by the end of August [14] Group 3: Regulatory Changes - New regulations on public fund sales management were released, which are expected to reduce annual sales costs by approximately 30 billion yuan, a decrease of 34% [15] - The new rules will lower the maximum subscription and purchase fees for equity funds from 1.2% and 1.5% to 0.8%, and for mixed funds from 1.2% and 1.5% to 0.5% [15] Group 4: Company News - Guizhou Moutai announced that its controlling shareholder has received a loan commitment letter from Agricultural Bank of China for a maximum of 2.7 billion yuan to support stock buybacks [19] - ST Zhitian received a decision from the Shenzhen Stock Exchange to terminate its stock listing, with the last trading date expected to be October 13, 2025 [20] - ST Lingnan is under investigation by the China Securities Regulatory Commission for suspected violations of information disclosure laws [21] Group 5: Market Trends - In the first half of 2025, 49 securities firms reported a total margin interest income of 43.2 billion yuan, showing a year-on-year growth of over 10% [16] - The A-share market will see over 960 billion yuan in locked-up shares released this week, with significant amounts from companies like Times Electric and South Network Storage [25]

Group 1: Hang Seng Index Changes - Hang Seng Index Company announced changes to its index series effective from September 8, 2025, increasing the number of constituent stocks from 85 to 88, with additions including China Telecom, JD Logistics, and Pop Mart [1] - The Hang Seng China Enterprises Index will maintain 50 constituent stocks, adding Pop Mart and removing Jitu Express [1] - The Hang Seng Composite Index will increase from 502 to 504 constituent stocks, adding China Foods and Hengrui Medicine, while removing Crown City Watch and Jewelry and Sipai Health [1] Group 2: Company News - *ST Zitian announced that the Shenzhen Stock Exchange has decided to terminate its stock listing due to false financial reporting, with trading resuming on September 15 and entering a delisting period of 15 trading days [4][5] - Zhongyin Securities held a board meeting and elected Zhou Quan as the chairman of the board, with his term lasting until the end of the current board's term [5] - Tonghui Information received a notice of administrative penalty from Beijing Securities Regulatory Bureau, with a proposed fine of 35.5 million yuan for information disclosure violations [5][6] Group 3: Financial Misreporting - Tonghui Information and its subsidiaries inflated revenue and profits through fictitious contracts and premature or delayed revenue recognition from 2018 to 2021, resulting in false financial statements for those years [6] - The inflated revenues for the years 2018 to 2021 were reported as 20.173 million yuan, 9.617 million yuan, 14.976 million yuan, and 18.065 million yuan respectively, with corresponding profit inflation of 10.464 million yuan, 8.149 million yuan, 7.375 million yuan, and 5.878 million yuan [6]

Core Viewpoint - The influx of southbound capital has turned Hong Kong stocks into a "reservoir" for Asian capital, with significant investments flowing into the healthcare sector, particularly in companies like Four Seasons Pharmaceutical [1][3]. Group 1: Capital Inflow and Market Performance - As of September 3, 2025, southbound funds through the Hong Kong Stock Connect have totaled approximately 935.997 billion RMB, with the Hang Seng healthcare sector seeing a net inflow of 163.683 billion RMB [1]. - Four Seasons Pharmaceutical has experienced a substantial increase in stock holdings by southbound funds, rising from 528 million shares at the beginning of the year to 1.321 billion shares by September 3, representing an increase in ownership from 8.83% to 14.15% of total shares [1]. - The stock price of Four Seasons Pharmaceutical has surged over 140% year-to-date, reflecting strong market confidence [3]. Group 2: Financial Performance and Business Segments - Four Seasons Pharmaceutical has entered a profit turnaround phase, achieving a total revenue of approximately 1.146 billion RMB in the first half of 2025, a year-on-year increase of 20.7%, and a net profit of approximately 103 million RMB [4]. - The company's gross margin improved to 66.1%, up from 64.2% in the same period last year, indicating effective cost control and product optimization [4]. - The medical aesthetics segment is the primary revenue driver, generating approximately 580 million RMB in revenue, a year-on-year increase of 81.3%, with segment profit soaring by 215.3% [4]. - The innovative drug segment also showed significant growth, with revenue reaching 58 million RMB, a year-on-year increase of 96.6%, primarily driven by the sales of diabetes medications [4]. Group 3: R&D and Product Development - Research and development expenditures decreased by 21.9% to 153 million RMB, reflecting a shift towards commercialization as core products enter the market [5]. - The company has established a comprehensive product line in the medical aesthetics sector, including various injectables and devices, with significant market penetration [7]. - Four Seasons Pharmaceutical is actively exploring AI applications in medical aesthetics, aiming to enhance product development and market competitiveness [7]. Group 4: Dividend Policy and Market Valuation - The company announced an interim cash dividend of 0.99 RMB per share, continuing its history of consistent dividends since its listing in 2010, which reflects management's confidence in future cash flows [6]. - As of September 3, 2025, the market capitalization of Four Seasons Pharmaceutical was 15.1 billion HKD, while the estimated valuation of its medical aesthetics business and cash reserves exceeds 17.3 billion HKD, indicating that the market has not assigned any value to its innovative drug segment [15][17]. - The management has demonstrated confidence in the company's future by executing 12 share buybacks in 2025, totaling approximately 94.867 million RMB [15].